H2DCFDA|CAS 4091-99-0|DC Chemicals

Cas No.:	4091-99-0
Chemical Name:	H2DCFDA
Synonyms:	2-(3,6-Diacetoxy-2,7-dichloro-9H-xanthen-9-yl)benzoic acid;DCFH-DA;2-(3,6-diacetyloxy-2,7-dichloro-9H-xanthen-9-yl)benzoic acid;2',7'-Dichlorodihydrofluorescein Diacetate;2,7-Dichlorodihydrofluorescein diacetate;2',7'-DICHLOROFLUORESCIN DIACETATE [2',7'-DICHLORODIHYDROFLUORESCEIN DIACETATE];2′,7′-Dichlorofluorescin diacetate;Benzoic acid,2-[3,6-bis(acetyloxy)-2,7-dichloro-9H-xanthen-9-yl]-;H2DCFDA [2'',7''-Dichlorodihydrofluorescein diacetate];H2DCFDA [2',7'-Dichlorodihydrofluorescein diacetate];2',7'-dichlorofluorescin diacetate;AC1L2TNZ;AC1Q1LBA;DCFH;H2DCFDA;Leucodiacetyldichlorofluorescein;ST067123;2′,7′-Dichlorodihydrofluorescein diacetate;2',7'-Dichlorofluorescein diacetate;2',7'-Dichlorohydrofluorescein diacetate;Benzoic acid, 2-[3,6-bis(acetyloxy)-2,7-dichloro-9H-xanthen-9-yl]-;dichlorodihydrofluorescein;2-[3,6-Bis(acetyloxy)-2,7-dichloro-9H-xanthen-9-yl]benzoic Acid;Benzoic acid, 2-(3,6-bis(acetyloxy)-2,7-dichloro-9H-xanthen-9-yl)-;2′,7′-Dichlorofluorescin Diacetate;DCFH-DA; 2',7'-Dichlorodihydrofluorescein diacetate;H2DCFDA (2 inverted exclamation marka,7 inverted exclamation marka-dichlorodihydrofluorescein diacetate);DTXSID9063293;FT-0610748;Q3026532;2,7-Dichlorodihydrofluoresceindiacetate;AS-72037;HY-D0940;A873196;SY075534;CS-7539;4091-99-0;2',7'-Dichlorodihydrofluorescein diacetateDCFH-DA;BCP20268;s9687;2-(2,7-Dichloro-3,6-diacetyloxy-9H-xanthen-9-yl)benzoic acid;PXEZTIWVRVSYOK-UHFFFAOYSA-N;MFCD00128955;H2DCFDA(DCFH-DA);A03-0014;AKOS015889059;2',7'-Dichlorofluorescin Diacetate - CAS 4091-99-0;SCHEMBL12361545;2',7'-Dichlorofluorescin diacetate, >=97%;2 inverted exclamation marka,7 inverted exclamation marka-Dichlorofluorescin diacetate;C24H14CI2O7;HB8322;DA-53807;DCFDA / H2DCFDA - Cellular ROS Assay Kit;2',7'-Dichlorodihydrofluorescein diacetate , DCFH-DA;HB7375;2-[3,6-Bis(acetyloxy)-2,7-dichloro-9H-xanthen-9-yl]benzoic Acid; o-(2,7-Dichloro-3,6-dihydroxyxanthen-9-yl)benzoic Acid Diacetate; 2',7'-Dichlorodihydrofluorescein Diacetate; DCFH; H2DCFDA;
SMILES:	ClC1C(=CC2=C(C=1)C(C1C=CC=CC=1C(=O)O)C1C=C(C(=CC=1O2)OC(C)=O)Cl)OC(C)=O
Formula:	C₂₄H₁₆Cl₂O₇
M.Wt:	487.285645484924

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.